Eagle Bay Advisors’s Kyntra Bio KYNB Stock Holding History

Eagle Bay Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16	Closed	-$5K	–	539
2021 Q4	$5K	Buy	+16	New	+$4.98K	﹤0.01%	787

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Eagle Bay Advisors's KYNB Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Kyntra Bio (KYNB) in Q1 2022, closing a stake of 16 shares — an estimated $5K sold.

Eagle Bay Advisors first reported a position in KYNB in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 156 funds tracked by Wall St. Rank hold KYNB as of Q1 2022.

Eagle Bay Advisors reported no remaining Kyntra Bio position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 16 Kyntra Bio shares in Q1 2022, an estimated $5K.
Eagle Bay Advisors first reported a position in Kyntra Bio in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Kyntra Bio position peaked at $5K in Q4 2021.
156 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.